656 related articles for article (PubMed ID: 16715965)
1. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
4. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
5. [Progress in the management of multiple myeloma introduced by serum free light chain measurement].
Fuchida S; Shimazaki C
Nihon Rinsho; 2011 Dec; 69(12):2267-73. PubMed ID: 22242331
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
[TBL] [Abstract][Full Text] [Related]
8. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
9. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
[TBL] [Abstract][Full Text] [Related]
10. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
[TBL] [Abstract][Full Text] [Related]
11. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
Bidet A; Marit G; Bérard AM
Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.
Levinson SS
Ann Clin Lab Sci; 2010; 40(4):348-53. PubMed ID: 20947809
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
16. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
17. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
Gottenberg JE; Aucouturier F; Goetz J; Sordet C; Jahn I; Busson M; Cayuela JM; Sibilia J; Mariette X
Ann Rheum Dis; 2007 Jan; 66(1):23-7. PubMed ID: 16569685
[TBL] [Abstract][Full Text] [Related]
19. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
